These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. Use of site-specified tritium labelling to confirm the formation of 17-oxosparteine as a minor urinary metabolite of sparteine in man. Ritchie JC; Mitchell SC; Smith RL; Zhang AQ Xenobiotica; 1996 Sep; 26(9):977-82. PubMed ID: 8893044 [TBL] [Abstract][Full Text] [Related]
31. A dose-effect study of the in vivo inhibitory effect of quinidine on sparteine oxidation in man. Nielsen MD; Brøsen K; Gram LF Br J Clin Pharmacol; 1990 Mar; 29(3):299-304. PubMed ID: 2310654 [TBL] [Abstract][Full Text] [Related]
32. Inter-ethnic difference in sparteine oxidation among Ghanaians and Germans. Eichelbaum M; Woolhouse NM Eur J Clin Pharmacol; 1985; 28(1):79-83. PubMed ID: 3987789 [TBL] [Abstract][Full Text] [Related]
34. Sparteine metabolism in a Nigerian population. Ritchie JC; Mitchell SC; Smith RL Drug Metabol Drug Interact; 1996; 13(2):129-35. PubMed ID: 8905244 [TBL] [Abstract][Full Text] [Related]
35. Benzbromarone biotransformation is not related to polymorphic oxidation of sparteine. Walter-Sack I; Eichelbaum M; de Vries JX; Weber E Klin Wochenschr; 1988 Nov; 66(21):1097-8. PubMed ID: 3236759 [No Abstract] [Full Text] [Related]